Gilead Sciences has reported mid-stage trial results showing its experimental oral therapy emvistegrast induced clinical remission in patients with moderate to severe ulcerative colitis. In the Phase 2 study, a 200 mg daily dose taken for 12 weeks produced a 23% placebo-adjusted clinical remission rate, a statistically significant improvement that surpassed analyst expectations.
The data, reported Monday, strengthen Gilead's push into inflammatory and autoimmune disease treatments. Swati Tole, the company's senior vice president overseeing inflammatory disease drug development, said the results were encouraging and that emvistegrast has the potential to be a best-in-class oral option for ulcerative colitis patients. She noted that many patients on existing therapies still have persistent symptoms and that most do not achieve remission.
While these are early, Phase 2 findings, the size of the effect and the convenience of an oral pill could make emvistegrast a notable contender in the IBD market if later-stage trials confirm the benefit. Gilead has not yet outlined next steps, but the drug is widely expected to advance toward Phase 3 testing.